drugset / Trial / NCT05624294
Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS0159 in Chinese Healthy Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a phase I clinical bridging trial, randomized, double-blind, placebo-controlled, single ascending does/ mulelple ascending does study of CS0159 to evaluate the safety, tolerability, pharmacokynetics, pharmacodynamices, and food effect in Chinese healthy subjects.
Timeline
- Start
- 2022-12-19
- Primary completion
- 2023-03-28
- Completion
- 2023-03-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CS0159 | Unknown | 2 mg | Oral |
| Subject | CS0159 | Unknown | 4 mg | Oral |
| Subject | CS0159 | Unknown | 6 mg | Oral |